Immune therapies against chronic hepatitis B

by Ehime UniversityTwo main types of immune therapies have been employed to treat chronic hepatitis B during the last 4 decades. However, it seems that HBV-antigen-specific immune therapy may be safe

Updated on: May 29,2024 7

Immune therapies against chronic hepatitis B

by Ehime UniversityTwo main types of immune therapies have been employed to treat chronic hepatitis B during the last 4 decades. However, it seems that HBV-antigen-specific immune therapy may be safe

Updated on:May 29,2024 7

Hepatitis B: 'Sleep timer' for immune cells discovered

byTechnical University MunichA virus-specific T cell (blue) in the vascular system of a liver with chronic hepatitis B virus infection. Credit: Percy A. Knolle / TUMIn chronic hepatitis B, the l

Updated on: July 15,2024 0

Hepatitis B: 'Sleep timer' for immune cells discovered

byTechnical University MunichA virus-specific T cell (blue) in the vascular system of a liver with chronic hepatitis B virus infection. Credit: Percy A. Knolle / TUMIn chronic hepatitis B, the l

Updated on:July 15,2024 0

Scientists find omega-3 lysolipids may prevent fatty liver disease

by Duke-NUS Medical SchoolDetection of the lysolipid transporter Mfsd2a in hepatocytes, stained green, in proximity to a bile duct, stained magenta. Credit: Chin Cheen FeiLong-running research by

Updated on: June 03,2024 8

Scientists find omega-3 lysolipids may prevent fatty liver disease

by Duke-NUS Medical SchoolDetection of the lysolipid transporter Mfsd2a in hepatocytes, stained green, in proximity to a bile duct, stained magenta. Credit: Chin Cheen FeiLong-running research by

Updated on:June 03,2024 8

Liver cancer 'signature' in gut holds clues to cancer risk

by Caroline Tang,University of New South WalesCredit: Thirdman from PexelsPeople with non-alcohol-related liver cancer have a unique gut microbiome profile which could help predict disease risk,

Updated on: June 20,2024 6

Liver cancer 'signature' in gut holds clues to cancer risk

by Caroline Tang,University of New South WalesCredit: Thirdman from PexelsPeople with non-alcohol-related liver cancer have a unique gut microbiome profile which could help predict disease risk,

Updated on:June 20,2024 6

The role of non-parenchymal cells in liver metabolism and disease

Updated on: July 20,2024 0

The role of non-parenchymal cells in liver metabolism and disease

Updated on:July 20,2024 0

Popular diabetes drug may also reduce the risk of severe liver disease

by Karolinska InstitutetCredit: Pixabay/CC0 Public DomainOzempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes

Updated on: June 01,2024 6

Popular diabetes drug may also reduce the risk of severe liver disease

by Karolinska InstitutetCredit: Pixabay/CC0 Public DomainOzempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes

Updated on:June 01,2024 6

Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

by Elana GotkineFor patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, accordi

Updated on: July 10,2024 0

Study compares rivaroxaban, warfarin with apixaban for cirrhosis, atrial fibrillation

by Elana GotkineFor patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiators of rivaroxaban or warfarin versus apixaban have significantly higher rates of major hemorrhage, accordi

Updated on:July 10,2024 0

Enhancing Anti-Tumor Immune Response in Small Cell Lung Cancer Through Combined Radiotherapy and CD47 Blockade: Mechanisms and Therapeutic Potential

Updated on: July 20,2024 0

Enhancing Anti-Tumor Immune Response in Small Cell Lung Cancer Through Combined Radiotherapy and CD47 Blockade: Mechanisms and Therapeutic Potential

Updated on:July 20,2024 0

Gut microbiota harnessed as tool to diagnose diseases, promising results for fatty liver diagnosis

by University of JyväskyläThe diversity of the gut microbiota in the low (n = 25) and high (n = 37) liver fat groups. (A) Shannon index, a measure of alpha-diversity indicating species diversity.

Updated on: May 29,2024 4

Gut microbiota harnessed as tool to diagnose diseases, promising results for fatty liver diagnosis

by University of JyväskyläThe diversity of the gut microbiota in the low (n = 25) and high (n = 37) liver fat groups. (A) Shannon index, a measure of alpha-diversity indicating species diversity.

Updated on:May 29,2024 4

Universal gut microbiome-derived signature predicts cirrhosis

by University of California - San DiegoIllustration depicts a healthy liver (left) and a liver with cirrhosis. Credit: National Institute of Diabetes and Digestive and Kidney DiseasesNonalcoholic

Updated on: May 28,2024 7

Universal gut microbiome-derived signature predicts cirrhosis

by University of California - San DiegoIllustration depicts a healthy liver (left) and a liver with cirrhosis. Credit: National Institute of Diabetes and Digestive and Kidney DiseasesNonalcoholic

Updated on:May 28,2024 7

Study finds cirrhosis affects twice as many transgender adults as cisgender adults

byUniversity of Southern CaliforniaCredit:American Journal of Gastroenterology(2024). DOI: 10.14309/ajg.0000000000002907Cirrhosis is chronic, progressive end-stage liver disease that

Updated on: July 11,2024 0

Study finds cirrhosis affects twice as many transgender adults as cisgender adults

byUniversity of Southern CaliforniaCredit:American Journal of Gastroenterology(2024). DOI: 10.14309/ajg.0000000000002907Cirrhosis is chronic, progressive end-stage liver disease that

Updated on:July 11,2024 0

Study shows seladelpar beneficial for patients with primary biliary cholangitis

by Elana GotkineFor patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline p

Updated on: June 04,2024 6

Study shows seladelpar beneficial for patients with primary biliary cholangitis

by Elana GotkineFor patients with primary biliary cholangitis, more receiving the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar have a biochemical response and alkaline p

Updated on:June 04,2024 6